Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "metabolic-diseases"

27 News Found

NAFLD clinical trial activity catching up in China but lacks substantial domestic participation, says GlobalData
News | December 27, 2022

NAFLD clinical trial activity catching up in China but lacks substantial domestic participation, says GlobalData

China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.


Experts highlight the rising cases of diabetes in youngsters
Healthcare | November 16, 2022

Experts highlight the rising cases of diabetes in youngsters

India is home to nearly 80 million diabetics and this number is expected to rise to a staggering 134 million in the next 25 years.


NewAmsterdam Pharma shares new data from Phase 2b ROSE Study
News | June 07, 2022

NewAmsterdam Pharma shares new data from Phase 2b ROSE Study

82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo


Lupin signs deal with Alvion for cardiometabolic drugs in Southeast Asia
Biotech | April 05, 2022

Lupin signs deal with Alvion for cardiometabolic drugs in Southeast Asia

Lupin is committed to providing new affordable treatment options to healthcare providers and patients


Abbisko Therapeutics enters global tie-up with Lilly to develop novel molecules
Biotech | January 18, 2022

Abbisko Therapeutics enters global tie-up with Lilly to develop novel molecules

The tie-up combines Abbisko Therapeutics’ proprietary drug discovery platform with Lilly’s disease and discovery expertise


Twin Health raises US $ 140 million in Series C funding
Startup | October 07, 2021

Twin Health raises US $ 140 million in Series C funding

The start-up claims in clinical trials over 90 % achieved type 2 diabetes reversal and 92 % eliminated all diabetes medication within 90 days of joining the twin service


Poxel and Sumitomo Dainippon gets TWYMEEG approval
News | June 25, 2021

Poxel and Sumitomo Dainippon gets TWYMEEG approval

The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies